We would like to thank all of our clients for making Kempen & Co the most active ECM bank in the Benelux last year! kempen.com/en/corporate-f… #ECM

Happy Valentine’s Day from the heart of European Life Sciences! The 13th Kempen Life Sciences conference will be held on 21 & 22 April. 2019: almost 50 companies and over 100 investors 2020: it promises to be even busier. kempen.com/en/securities/…

Kempen adviser in sale TerraPay by @MahindraComviva to Prime Ventures and Partech. Joined by IFC also participated in a capital increase to fund TerraPay’s global expansion. Congratulations to TerraPay’s founders Ambar Sur, Ram Sundaram, Ani Sane & Akbar Hussain

Kempen analyst Alex Cogut comments on the development of #COVID19 tests in Dutch national newspaper De Telegraaf: “German-Dutch biotech Qiagen probably the first with a test on the US market.” telegraaf.nl/financieel/103…

The search for a drug or vaccine for coronavirus is in full swing with more and more parties (like $BNTX) joining the global effort - with insights from our vaccines analyst Suzanne! #biotech #vaccines #coronavirus BioNTech SE

Life Sciences analyst Suzanne van Voorthuizen comments in Dutch newspaper NRC about the development of a vaccine for #Covid_19: ‘Investing in vaccines is an uncertain business and not always viable.’ nrc.nl/nieuws/2020/03…

Our managing director Securities Anneka Treon discusses in The Financial Times the role of banks in this crisis; behaving more like shock absorbers than shock amplifiers, as they were over 2007-2008. ft.com/content/1ff7c4… #banking #covid19 #economy #leverage

Our colleague Stan van Wersch explains in Dutch newspaper NRC about doing his work as a trader with the #COVID2019NL restrictions: “I still cycle to the office everyday.” nrc.nl/nieuws/2020/04…

Life sciences analysts Suzanne van Voorthuizen and Alex Cogut were quoted in Dutch newspaper De Telegraaf about pricing of treatments and vaccins telegraaf.nl/financieel/190…

Analyst Jaap Kuin in Dutch FD Nieuws about the price increase of Unibail-Rodamco-Westfield: 'Any snippet of positive news, for example about the reopening of shopping centers, can now lead to serious price increases. It mainly reflects the uncertainty in the market' fd.nl/beurs/1345944/…

Kempen & Co is pleased to announce it acted as Co-Manager the largest capital increase to date of its long-term client #argenx - setting a new landmark for European biotech by raising USD 750 million in gross proceeds kempen.com/en/corporate-f…

Analist Jaap Kuin comments in De Telegraaf today about the retail property sector in The Netherlands - written by Johan Wiering and Pieter van Erven Dorens Unibail-Rodamco-Westfield telegraaf.nl/financieel/185…

Head of Kempen's Real Estate Research Robert Woerdeman is sceptical about the modest price increase in the retail real estate stock market (article in Dutch) deaandeelhouder.nl/nieuws/2020/06…

Kempen & Co acted as Joint Global Coordinator in BioInvent’s Capital Increase of SEK 487 million. This deal marks our sixth transaction in the Nordics region over the past 18 months, where we maintain a strong ambition to work with innovative companies. kempen.com/en/corporate-f…

Register now! During the webinar on June 26, ProQr's Daniel de Boer delves into the impact of COVID-19 on financing in the #lifesciences w/ Geraldine O'Keeffe (LSP), Arthur Franken (Gilde Healthcare), Krijn De Nood (Meatable) & Jan De Kerpel (Kempen & Co). lnkd.in/d9k9u_W

Our Life Sciences analyst Suzanne van Voorthuizen today in De Telegraaf about 'the hunt for eternal fame with a coronavaccin': "Biotech companies feel, above all, a moral obligation to work on a solution" telegraaf.nl/financieel/989…

Our MD at Securities #AnnekaTreon commented yesterday about the current state of equity markets on #Bloomberg TV #stocks #economicrecovery #fiscalpolicy #equities #stockmarket #centralbanks #investments #investing #financialmarkets #finance bloomberg.com/news/videos/20…

The Oryzon Genomics’ Capital Increase of €20m is our 7th transaction for Euro #lifesciences companies in 2020 and our first ever for a Spanish LS company, underpinning our ambition to work with innovative LS companies in Europe. #biotech kempen.com/en/corporate-f…

We acted as Joint Global Coordinator / Joint Bookrunner in #Hyloris IPO of €61.8 million. Its the first #IPO on #Euronext Brussels in 2020, and Kempen & Co's 8th overall transaction for European #lifesciences companies since the beginning of 2020. kempen.com/nl/corporate-f…